Finding drug candidates to treat viral infections caused by coronaviruses

This project, in partnership with the startup Nintx and funding from EMBRAPII, is intended to develop pharmaceutical candidates to treat viral infections caused by coronaviruses. It is inspired by natural products and uses CNPEM protocols and advanced technology for pharmaceutical discovery. The first phase, which started in July 2022, looked for molecular hits from Brazil’s biology to inhibit selected viral proteins, pursing innovation in the development of antivirals to combat coronaviruses. The project is being conducted in stages, with a focus on finding differentiated treatments for illnesses caused by coronaviruses.